Ulrich Engelmann

Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS)

Raimar Kern, Tjalf Ziemssen, T. Ziemssen, 2016, BMC Neurology.

Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status

A. Chan, B. Kallmann, Ulrich Engelmann, 2021, Therapeutic advances in neurological disorders.

Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study

A. Chan, B. Kallmann, Ulrich Engelmann, 2019, Therapeutic advances in neurological disorders.

Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study

T. Ziemssen, S. Richter, Ulrich Engelmann, 2021, Frontiers in Neurology.